Chicago Partners Investment Group LLC boosted its stake in Pfizer Inc. (NYSE:PFE) by 4.1% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 53,693 shares of the biopharmaceutical company’s stock after acquiring an additional 2,091 shares during the quarter. Chicago Partners Investment Group LLC’s holdings in Pfizer were worth $2,077,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors also recently modified their holdings of PFE. Kinloch Capital LLC purchased a new position in Pfizer in the 4th quarter valued at about $25,000. Alpha DNA Investment Management LLC purchased a new position in shares of Pfizer in the fourth quarter valued at approximately $26,000. Penbrook Management LLC acquired a new stake in shares of Pfizer in the fourth quarter worth approximately $27,000. Orion Capital Management LLC purchased a new stake in shares of Pfizer during the fourth quarter worth approximately $29,000. Finally, Merrion Investment Management Co LLC acquired a new position in Pfizer in the 4th quarter valued at $30,000. 67.36% of the stock is owned by institutional investors.
A number of equities research analysts have recently issued reports on the stock. Berenberg Bank reaffirmed a “neutral” rating and set a $38.00 target price on shares of Pfizer in a report on Tuesday, March 23rd. Mizuho cut their price objective on shares of Pfizer from $44.00 to $42.00 and set a “buy” rating for the company in a report on Wednesday, February 3rd. The Goldman Sachs Group set a $41.00 target price on Pfizer and gave the stock a “neutral” rating in a report on Tuesday, April 6th. SVB Leerink cut their price target on Pfizer from $40.00 to $39.00 and set a “market perform” rating for the company in a report on Thursday, April 1st. Finally, DZ Bank reissued a “buy” rating and set a $41.00 price objective on shares of Pfizer in a research note on Wednesday, February 3rd. Eleven investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $38.47.
Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, February 2nd. The biopharmaceutical company reported $0.42 EPS for the quarter, missing the consensus estimate of $0.46 by ($0.04). The company had revenue of $11.68 billion during the quarter, compared to analyst estimates of $11.32 billion. Pfizer had a return on equity of 24.88% and a net margin of 17.85%. The business’s revenue was up 11.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.55 earnings per share. As a group, analysts anticipate that Pfizer Inc. will post 2.89 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 4th. Stockholders of record on Friday, May 7th will be paid a $0.39 dividend. This represents a $1.56 annualized dividend and a dividend yield of 3.92%. The ex-dividend date is Thursday, May 6th. Pfizer’s payout ratio is 52.88%.
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands.
Recommended Story: Stop Order Uses For Individual Investors
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.